Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALPANA A DESAI

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1477504223
CMS profile
293976
Location
STUART, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$2,275.60

148 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,270.60 147
Education $5.00 1

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALPANA A DESAI

NPI 1477504223 · CMS profile ID 293976

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

STUART, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1477504223?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALPANA A DESAI, NPI 1477504223, CMS profile ID 293976. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1477504223?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ALPANA A DESAI, NPI 1477504223, CMS profile ID 293976. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1477504223?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ALPANA A DESAI, NPI 1477504223, CMS profile ID 293976, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1477504223?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

148 matching records · $2,275.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 148 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 148.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Puma Biotechnology, Inc. $17.5608/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750537595 CMS
Merck Sharp & Dohme Corporation $11.6508/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747666287 CMS
E.R. Squibb & Sons, L.L.C. $14.3608/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727791729 CMS
Amgen Inc. $15.9408/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740894327 CMS
E.R. Squibb & Sons, L.L.C. $11.9508/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727791723 CMS
Bayer HealthCare Pharmaceuticals Inc. $13.2307/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713618095 CMS
E.R. Squibb & Sons, L.L.C. $14.4307/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727791705 CMS
E.R. Squibb & Sons, L.L.C. $14.3207/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727791717 CMS
E.R. Squibb & Sons, L.L.C. $11.6607/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727791707 CMS
Dova Pharmaceuticals $23.6407/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752353201 CMS
GlaxoSmithKline, LLC. $22.6107/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738835503 CMS
Bayer HealthCare Pharmaceuticals Inc. $13.2107/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713638017 CMS
Taiho Oncology, Inc. $13.9907/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724400645 CMS
Seagen Inc. $10.5807/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732433461 CMS
GENZYME CORPORATION $24.2307/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744200957 CMS
Amgen Inc. $23.5107/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741364735 CMS
Lexicon Pharmaceuticals, Inc. $17.6007/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751837801 CMS
Seagen Inc. $10.3807/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732433465 CMS
Clovis Oncology, Inc. $16.4207/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722233715 CMS
E.R. Squibb & Sons, L.L.C. $18.6207/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727791697 CMS
E.R. Squibb & Sons, L.L.C. $16.8207/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727791691 CMS
Dova Pharmaceuticals $21.6706/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752352999 CMS
AstraZeneca Pharmaceuticals LP $17.8706/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736006693 CMS
Lexicon Pharmaceuticals, Inc. $12.2506/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751837805 CMS
E.R. Squibb & Sons, L.L.C. $7.4006/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727791701 CMS
Bayer HealthCare Pharmaceuticals Inc. $9.0906/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713622711 CMS
Daiichi Sankyo Inc. $13.0906/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739491963 CMS
Bayer HealthCare Pharmaceuticals Inc. $11.9506/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713632869 CMS
Foundation Medicine, Inc. $14.7906/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 714555695 CMS
AstraZeneca Pharmaceuticals LP $16.0406/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736165575 CMS
AstraZeneca Pharmaceuticals LP $20.3406/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735824337 CMS
Seagen Inc. $10.3306/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732433435 CMS
Genentech USA, Inc. $11.8406/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742978361 CMS
Seagen Inc. $14.3306/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732433449 CMS
Clovis Oncology, Inc. $17.4706/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722233123 CMS
Seagen Inc. $14.0506/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732433439 CMS
GlaxoSmithKline, LLC. $13.7605/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738515245 CMS
SANOFI-AVENTIS U.S. LLC $18.1305/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744200903 CMS
Dova Pharmaceuticals $11.7805/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752352635 CMS
Sirtex Medical Inc $15.8605/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 734605933 CMS
Janssen Biotech, Inc. $16.1905/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718968033 CMS
AbbVie Inc. $12.8805/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721750715 CMS
Lexicon Pharmaceuticals, Inc. $12.5505/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751837799 CMS
Celgene Corporation $15.8005/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727791755 CMS
E.R. Squibb & Sons, L.L.C. $14.2805/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727791673 CMS
Daiichi Sankyo Inc. $14.7705/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739487717 CMS
Secura Bio, Inc. $9.2905/04/2020 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 733547847 CMS
Seagen Inc. $13.7804/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732433419 CMS
Janssen Biotech, Inc. $18.5704/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718968049 CMS
E.R. Squibb & Sons, L.L.C. $14.9204/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727791667 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,741.67 234
PY2020 $2,275.60 148
PY2021 $2,576.82 151
PY2022 $3,575.30 201
PY2023 $4,135.43 226
PY2024 $4,115.83 210
PY2025 $4,057.63 206

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $440,384.00 8
PY2024 Principal investigator $90,336.92 4
PY2023 Principal investigator $40,151.00 3
PY2022 Principal investigator $4,523.58 3
PY2021 Principal investigator $43,831.01 41

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

8 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $26,867.70 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185543020
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,200.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185543028
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,775.78 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185543018
Principal investigator 1 AstraZeneca Pharmaceuticals LP $135,792.85 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 No dispute reported 06/30/2026 1185543022
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,300.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185543024
Principal investigator 1 AstraZeneca UK Limited $131,406.67 03/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 No dispute reported 06/30/2026 1185543016
Principal investigator 1 AstraZeneca Pharmaceuticals LP $32,800.00 02/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185543030
Principal investigator 1 AstraZeneca UK Limited $86,241.00 02/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 No dispute reported 06/30/2026 1185543026